Compare Novartis AG (NVS) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Consumer Staples Select Sector SPDR Fund — how do they compare? Novartis AG trades at $139.3 (market cap $262.64B), while Consumer Staples Select Sector SPDR Fund trades at $83.19. The key difference: Novartis AG pays a 3.44% dividend while Consumer Staples Select Sector SPDR Fund pays none, and Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | XLP | |
|---|---|---|
Market Cap | $262.64B | — |
Sector | Health | — |
52-Week High | $168.62 | $90.00 |
52-Week Low | $121.80 | $75.61 |
Enterprise Value | $303.97B | — |
Dividend Yield | 3.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
XLP (Consumer Staples Select Sector SPDR ETF) trades at $84.02, down 0.66% on the day amid broader market volatility. The technical picture shows bearish momentum with selling pressure outweighing buying signals 14 to 6, though oscillators suggest potential stabilization. Analyst consensus remains strongly positive with 100% buy ratings, highlighting XLP's defensive characteristics during economic uncertainty. Recent news emphasizes the fund's appeal as a safe haven with its 2.6% dividend yield and exposure to stable consumer staples companies.
XLP offers defensive exposure to essential consumer goods companies, providing stability during market turbulence. The fund's low 0.08% expense ratio and consistent dividend payments support its appeal for risk-averse investors. However, limited growth potential compared to cyclical sectors and sensitivity to consumer spending trends present ongoing challenges for significant price appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
